ArticleBMC veterinary research2025
Development of an indirect ELISA based on a new specific lipoprotein LP53 for the detection of antibodies against Mycoplasma synoviae.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic Diversity and Emerging Trends ofMicroorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMycoplasma synoviae (MS) is considered to be one of the main mycoplasma pathogens of poultry, causing arthritis, airsacculitis, eggshell apex abnormalities and production drops in chickens and turkeys. Infection by MS usually results in considerable economic losses to the poultry industry worldwide. Therefore, it is essential to develop a highly sensitive and accurate diagnostic method in the livestock production.
resultsThe MSLP53 was predicted as a highly conserved and specific membrane associated lipoprotein of MS by bioinformatics analysis. The His-tagged MSLP53 (rMSLP53) protein was expressed and purified using E. coli expression system, and was confirmed by Western blotting to react with each MS-positive serum, but not react with positive sera against other avian pathogens, suggesting that the rMSLP53 had strong immunoreactivity and specificity. An rMSLP53-based indirect ELISA was developed, compared to IDEXX kit with a pool of 277 chicken sera samples, and showed high sensitivity (85.54%), specificity (89.19%) and coincidence rate (87.00%) within these two methods. When detecting the sera from experimentally infected chickens, the newly established rMSLP53-ELISA had certain advantages over the IDEXX kit, that is, it could identify the serum 3–18 weeks after infection as MS-positive serum, while IDEXX kit could only identify the serum 3–12 weeks after infection as positive serum.
conclusionThe MSLP53 protein is a specific immunogenic lipoprotein of MS, which was confirmed to be a promising antigen target for the detection of serum antibodies of MS. A rMSLP53-based indirect ELISA assay was successfully established in this study, showed high sensitivity, specificity and consistency with the commercial IDEXX kit, and could recognize the serum as MS-positive in a longer period after MS infection than IDEXX kit. This newly established rMSLP53-ELISA may be used as an effective detection method for MS serological monitoring and epidemiological investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.